Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

National Survey Finds Six In Ten Americans Believe Serious Outbreak Of Influenza A (H1N1) Likely In Fall/Winter
As part of a series about Americans" response to the H1N1 flu outbreak, the Harvard Opinion Research Program at the Harvard School of Public Health is releasing a national poll that focuses on Americans" views and concerns about the potential for a more severe outbreak of Influenza A (H1N1) in the fall or winter. The polling was done June 22-28, 2009.

Shedding Light On Preserving Fertility Among Cancer Patients
Cancer treatment has come a long way, leading to a multitude of therapy options and improved survival rates. These successes, however, have created a challenge for young cancer patients since chemotherapy and radiation treatments that often save lives threaten fertility. Techniques available to safeguard fertility, such as freezing eggs for later embryo development, have poor odds of success, leaving patients with very limited options for the future. But that is beginning to change as researchers improve current techniques, mature human eggs in the laboratory, and discover cellular mechanisms that could help preserve and even restore fertility. Researchers will report on these and other findings at the 42nd annual meeting of the Society for the Study of Reproduction (SSR), July 18 to 22, at the David L. Lawrence Convention Center in Pittsburgh.
News of the day
Pharming Receives Agreement On Paediatric Investigation Plan For Rhucin(R) From The EMEA Paediatric Committee
Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMEA) has adopted an opinion agreeing the paediatric investigation plan (PIP) for Rhucin® (recombinant human C1 inhibitor) in the therapeutic area of immunology-rheumatology transplantation.
Health Insurance

Mylan Receives FDA Approval For Generic Version Of Prostate Cancer Treatment Casodex(R)

Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bicalutamide Tablets, 50 mg. Bicalutamide Tablets are the generic version of AstraZeneca"s prostate cancer treatment Casodex(R), which had total U.S. sales of approximately $322 million for the 12 months ending March 31 for the same strength, according to IMS Health. Mylan has begun to ship this product. Currently, Mylan has 118 ANDAs pending FDA approval representing $82.8 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.7 billion in annual brand sales, according to IMS Health. Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry"s broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world"s third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. Mylan Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009